{"title":"氨基酸代谢相关基因亮氨酸- trna合成酶1 (LARS1)作为肝细胞癌潜在预后和治疗靶点的鉴定","authors":"Qiyu Shi, Yirong Chi, Ziyi Peng, Chao Li, Jingwen Zhao, Jie Zhang","doi":"10.3389/fonc.2025.1675018","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Amino acid metabolism plays a critical role in tumorigenesis in hepatocellular carcinoma (HCC). Thus, we explore the amino acid metabolic profile in HCC to construct effective prognosis model and identify novel potential therapeutic target for HCC.</p><p><strong>Methods: </strong>The transcriptomic data and clinical information of HCC patients were directly obtained from The Cancer Genome Atlas (TCGA). Then we classified them into two subtypes based on selected amino acid metabolism-related genes (SARGs) and explored the differences between them. Besides, risk models were constructed based on SARGs through LASSO regression, and we further validated and evaluated the predictive effect of the model. Subsequently, we validated the key gene of LARS1 in the model. We analyzed the discrepancy of LARS1 in tumor and adjacent non-tumor tissues in both TCGA and the Gene Expression Omnibus (GEO) database and the results were verified in HCC patients undergoing hepatectomy from our hospital via PCR and Immunohistochemistry (IHC). Finally, we explored the biological function of LARS1 <i>in vitro</i>.</p><p><strong>Results: </strong>We classified HCC patients into Cluster A and B subtypes based on 81 SARGs. And patients in Cluster B exhibited significantly poorer prognosis, higher tumor malignancy levels, higher TIDE scores and T cell exhaustion or dysfunction. Then 15 genes were included to construct the risk model. The risk score was positively associated with poor prognosis. We further extracted LARS1 as the key gene of the model and found that high LARS1 tended to have poorer prognosis with higher expression in tumor tissues than in adjacent non-tumor ones in both TCGA and GEO. PCR and IHC were conducted for verification. Suppression of LARS1 markedly inhibited the growth of HCC cells. Additionally, LARS1 knockdown significantly impeded cellular migration and invasion <i>in vitro</i>, with increased autophagy flux.</p><p><strong>Conclusion: </strong>We have successfully developed a prognostic model based on 15 genes associated with amino acid metabolism. We also verified that knockdown of LARS1 significantly inhibited the proliferation, invasion and migration of HCC <i>in vitro</i>, with increased autophagy flux, indicating that LARS1 could be a potential therapeutic target for HCC.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1675018"},"PeriodicalIF":3.5000,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12479282/pdf/","citationCount":"0","resultStr":"{\"title\":\"Identification of amino acid metabolism-related gene Leucyl-tRNA synthetase 1 (LARS1) as a potential prognostic and therapeutic target in hepatocellular carcinoma.\",\"authors\":\"Qiyu Shi, Yirong Chi, Ziyi Peng, Chao Li, Jingwen Zhao, Jie Zhang\",\"doi\":\"10.3389/fonc.2025.1675018\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Amino acid metabolism plays a critical role in tumorigenesis in hepatocellular carcinoma (HCC). Thus, we explore the amino acid metabolic profile in HCC to construct effective prognosis model and identify novel potential therapeutic target for HCC.</p><p><strong>Methods: </strong>The transcriptomic data and clinical information of HCC patients were directly obtained from The Cancer Genome Atlas (TCGA). Then we classified them into two subtypes based on selected amino acid metabolism-related genes (SARGs) and explored the differences between them. Besides, risk models were constructed based on SARGs through LASSO regression, and we further validated and evaluated the predictive effect of the model. Subsequently, we validated the key gene of LARS1 in the model. We analyzed the discrepancy of LARS1 in tumor and adjacent non-tumor tissues in both TCGA and the Gene Expression Omnibus (GEO) database and the results were verified in HCC patients undergoing hepatectomy from our hospital via PCR and Immunohistochemistry (IHC). Finally, we explored the biological function of LARS1 <i>in vitro</i>.</p><p><strong>Results: </strong>We classified HCC patients into Cluster A and B subtypes based on 81 SARGs. And patients in Cluster B exhibited significantly poorer prognosis, higher tumor malignancy levels, higher TIDE scores and T cell exhaustion or dysfunction. Then 15 genes were included to construct the risk model. The risk score was positively associated with poor prognosis. We further extracted LARS1 as the key gene of the model and found that high LARS1 tended to have poorer prognosis with higher expression in tumor tissues than in adjacent non-tumor ones in both TCGA and GEO. PCR and IHC were conducted for verification. Suppression of LARS1 markedly inhibited the growth of HCC cells. Additionally, LARS1 knockdown significantly impeded cellular migration and invasion <i>in vitro</i>, with increased autophagy flux.</p><p><strong>Conclusion: </strong>We have successfully developed a prognostic model based on 15 genes associated with amino acid metabolism. We also verified that knockdown of LARS1 significantly inhibited the proliferation, invasion and migration of HCC <i>in vitro</i>, with increased autophagy flux, indicating that LARS1 could be a potential therapeutic target for HCC.</p>\",\"PeriodicalId\":12482,\"journal\":{\"name\":\"Frontiers in Oncology\",\"volume\":\"15 \",\"pages\":\"1675018\"},\"PeriodicalIF\":3.5000,\"publicationDate\":\"2025-09-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12479282/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Frontiers in Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3389/fonc.2025.1675018\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fonc.2025.1675018","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
Identification of amino acid metabolism-related gene Leucyl-tRNA synthetase 1 (LARS1) as a potential prognostic and therapeutic target in hepatocellular carcinoma.
Introduction: Amino acid metabolism plays a critical role in tumorigenesis in hepatocellular carcinoma (HCC). Thus, we explore the amino acid metabolic profile in HCC to construct effective prognosis model and identify novel potential therapeutic target for HCC.
Methods: The transcriptomic data and clinical information of HCC patients were directly obtained from The Cancer Genome Atlas (TCGA). Then we classified them into two subtypes based on selected amino acid metabolism-related genes (SARGs) and explored the differences between them. Besides, risk models were constructed based on SARGs through LASSO regression, and we further validated and evaluated the predictive effect of the model. Subsequently, we validated the key gene of LARS1 in the model. We analyzed the discrepancy of LARS1 in tumor and adjacent non-tumor tissues in both TCGA and the Gene Expression Omnibus (GEO) database and the results were verified in HCC patients undergoing hepatectomy from our hospital via PCR and Immunohistochemistry (IHC). Finally, we explored the biological function of LARS1 in vitro.
Results: We classified HCC patients into Cluster A and B subtypes based on 81 SARGs. And patients in Cluster B exhibited significantly poorer prognosis, higher tumor malignancy levels, higher TIDE scores and T cell exhaustion or dysfunction. Then 15 genes were included to construct the risk model. The risk score was positively associated with poor prognosis. We further extracted LARS1 as the key gene of the model and found that high LARS1 tended to have poorer prognosis with higher expression in tumor tissues than in adjacent non-tumor ones in both TCGA and GEO. PCR and IHC were conducted for verification. Suppression of LARS1 markedly inhibited the growth of HCC cells. Additionally, LARS1 knockdown significantly impeded cellular migration and invasion in vitro, with increased autophagy flux.
Conclusion: We have successfully developed a prognostic model based on 15 genes associated with amino acid metabolism. We also verified that knockdown of LARS1 significantly inhibited the proliferation, invasion and migration of HCC in vitro, with increased autophagy flux, indicating that LARS1 could be a potential therapeutic target for HCC.
期刊介绍:
Cancer Imaging and Diagnosis is dedicated to the publication of results from clinical and research studies applied to cancer diagnosis and treatment. The section aims to publish studies from the entire field of cancer imaging: results from routine use of clinical imaging in both radiology and nuclear medicine, results from clinical trials, experimental molecular imaging in humans and small animals, research on new contrast agents in CT, MRI, ultrasound, publication of new technical applications and processing algorithms to improve the standardization of quantitative imaging and image guided interventions for the diagnosis and treatment of cancer.